Veracyte, Inc.
VCYT
$30.43
-$0.53-1.71%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 445.76M | 425.33M | 399.58M | 375.47M | 361.05M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 445.76M | 425.33M | 399.58M | 375.47M | 361.05M |
| Cost of Revenue | 152.03M | 144.34M | 138.02M | 134.10M | 125.67M |
| Gross Profit | 293.73M | 280.99M | 261.56M | 241.37M | 235.38M |
| SG&A Expenses | 198.11M | 196.24M | 188.56M | 184.21M | 188.09M |
| Depreciation & Amortization | 14.85M | 15.80M | 17.34M | 18.89M | 20.57M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 418.32M | 409.10M | 392.39M | 381.74M | 378.87M |
| Operating Income | 27.44M | 16.24M | 7.19M | -6.26M | -17.81M |
| Income Before Tax | 25.74M | -8.17M | -54.79M | -70.43M | -76.61M |
| Income Tax Expenses | 1.61M | 1.10M | -750.00K | -2.25M | -2.21M |
| Earnings from Continuing Operations | 24.14 | -9.27 | -54.04 | -68.18 | -74.40 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 24.14M | -9.27M | -54.04M | -68.18M | -74.40M |
| EBIT | 27.44M | 16.24M | 7.19M | -6.26M | -17.81M |
| EBITDA | 50.90M | 39.78M | 32.18M | 19.85M | 9.37M |
| EPS Basic | 0.31 | -0.14 | -0.74 | -0.93 | -1.02 |
| Normalized Basic EPS | 0.30 | 0.26 | 0.16 | 0.03 | -0.08 |
| EPS Diluted | 0.30 | -0.15 | -0.75 | -0.94 | -1.03 |
| Normalized Diluted EPS | 0.30 | 0.26 | 0.16 | 0.03 | -0.08 |
| Average Basic Shares Outstanding | 305.92M | 301.42M | 297.21M | 293.15M | 290.57M |
| Average Diluted Shares Outstanding | 310.29M | 303.49M | 297.83M | 293.15M | 290.57M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
